Ceftazidime in patients with impaired renal function. Studies on pharmacokinetics and nephrotoxicity.
Thurmann-Nielsen
E
E
Department of Pharmacology and Toxicology, Faculty of Medicine, University of Trondheim, Trondheim, Norway.
Walstad
R A
RA
Dahl
K
K
Hellum
K B
KB
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics / Q000633:toxicity; D002442:Ceftazidime / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000633:toxicity; D003404:Creatinine / Q000378:metabolism; D005260:Female; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D007668:Kidney / Q000187:drug effects* / Q000473:pathology; D007674:Kidney Diseases / Q000378:metabolism*; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D014552:Urinary Tract Infections / Q000097:blood / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D002442:Ceftazidime; D003404:Creatinine